White House trade adviser Peter Navarro criticized the Food and Drug Administration’s decision to revoke emergency use authorization for the controversial drug hydroxychloroquine for treating the coronavirus after a study showed the possible benefits of the drug.

“The FDA decisions that they made, which I think were precipitous and based on bad science, had a tremendously negative effect on two things,” Navarro told reporters Tuesday, adding that people can no longer take the drug as a prophylactic and that hospitals cannot recruit subjects for clinical trials to test for the drug’s safety and efficacy.